6-Cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6-Cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione
• 英文别名: 6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione
• 化学式: C₃₀H₃₉FN₄O₄
• 分子量: 538.7
• InChiKey: WGYPAJVJMXQXTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  39
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  99.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] TREATMENT OF ENTERAL FEEDING INTOLERANCE AND MUSCLE WASTING<br/>[FR] TRAITEMENT DE L'INTOLÉRANCE À L'ALIMENTATION ENTÉRALE ET DE L'ATROPHIE MUSCULAIRE
  申请人：LYRIC PHARMACEUTICALS INC

  公开号：WO2017197131A1

  公开（公告）日：2017-11-16

  Enteral feeding intolerance and conditions associated with loss of muscle mass can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Ulimorelin is administered to: intensive care unit patients; intensive care unit patients with enteral feeding intolerance; patients requiring an increase in muscle mass, slowing the rate of muscle loss, or treating diseases associated with muscle loss; and populations of intensive care unit patients. Other features of the invention include dosing concentrations and schedules, methods of diagnosing and monitoring patients and specific patient populations.
• [EN] TREATMENT OF ENTERAL FEEDING INTOLERANCE AND MUSCLE WASTING WITH RELAMORELIN<br/>[FR] TRAITEMENT DE L'INTOLÉRANCE À L'ALIMENTATION ENTÉRALE ET DE L'AMYOTROPHIE À L'AIDE DE RELAMORÉLINE
  申请人：LYRIC PHARMACEUTICALS INC

  公开号：WO2017197328A1

  公开（公告）日：2017-11-16

  Enteral Feeding Intolerance (EFI) and conditions associated with loss of muscle mass can be efficaciously treated by administration of therapeutically effective doses of relamorelin every 8 hours (three times a day). Therapeutic benefit can be obtained from single and consecutive daily dosing, including for periods of up to a week or longer.